Complementary and Alternative Medical Therapies for Attention-Deficit/Hyperactivity Disorder and Autism

Pediatric Clinics of North America

Volumn 54, Issue 6, 2007, Pages 983-1006

  Weber, Wendy ^a   Newmark, Sanford ^b,c  

^a BASTYR UNIVERSITY   (United States)

^b Center for Pediatric Integrative Medicine   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARACHIDONIC ACID; ATOMOXETINE; BETAINE; CLONIDINE; DEXAMPHETAMINE; DIMETHYLGLYCINE; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; FOLINIC ACID; HEAVY METAL; ICOSAPENTAENOIC ACID; MERCURY; METHYLPHENIDATE; MINERAL; MULTIVITAMIN; OLIVE OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; PROBIOTIC AGENT; PYRIDOXINE; SUGAR; VITAMIN; ZINC;

ALTERNATIVE MEDICINE; ATTENTION DEFICIT DISORDER; AUTISM; AUTOIMMUNITY; BEHAVIOR THERAPY; CLINICAL TRIAL; DEVELOPMENTAL COORDINATION DISORDER; DIET THERAPY; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DRUG SAFETY; DYSBIOSIS; DYSLEXIA; ELECTROENCEPHALOGRAPHY; ENVIRONMENTAL EXPOSURE; EVIDENCE BASED MEDICINE; FEINGOLD DIET; FOOD ALLERGY; GASTROINTESTINAL DISEASE; GLUTATHIONE METABOLISM; HOMEOPATHY; HUMAN; HYPERACTIVITY; LEARNING DISORDER; MASSAGE; METABOLIC DISORDER; PSYCHOPHYSIOLOGY; REVIEW; SPEECH THERAPY; TABLET; UNSPECIFIED SIDE EFFECT; YOGA;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; CHILD; COMPLEMENTARY THERAPIES; FOOD HYPERSENSITIVITY; HOMEOPATHY; HUMANS; MASSAGE; MINERALS; PHYTOTHERAPY; VITAMINS; YOGA;

EID: 36549021568     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2007.09.006     Document Type: Review

References (95)

1. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics 105 5 (2000) 1158-1170
2. Biederman J., and Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 366 9481 (2005) 237-248
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition (1995), APA, Washington, DC
4. Schachter H.M., Pham B., King J., et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165 11 (2001) 1475-1488
5. Stockl K.M., Hughes T.E., Jarrar M.A., et al. Physician perceptions of the use of medications for attention deficit hyperactivity disorder. J Manag Care Pharm 9 5 (2003) 416-423
6. Michelson D., Allen A.J., Busner J., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159 11 (2002) 1896-1901
7. New warning about ADHD drug. FDA Consum 39 2 (2005) 3
8. Miller M.C. What is the significance of the new warnings about suicide risk with Strattera?. Harv Ment Health Lett 22 6 (2005) 8
9. In: Nissen D. (Ed). Mosby's drug consult 2003. 13th edition (2003), Mosby, St. Louis (MD)
10. Nissen S.E. ADHD drugs and cardiovascular risk. N Engl J Med 354 14 (2006) 1445-1448
11. Dosreis S., Zito J.M., Safer D.J., et al. Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder. J Dev Behav Pediatr 24 3 (2003) 155-162
12. Stubberfield T., and Parry T. Utilization of alternative therapies in attention-deficit hyperactivity disorder. J Paediatr Child Health 35 5 (1999) 450-453
13. Andersen S.L., and Navalta C.P. Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs. Int J Dev Neurosci 22 5-6 (2004) 423-440
14. Faraone S.V., Biederman J., Weber W., et al. Psychiatric, neuropsychological, and psychosocial features of DSM-IV subtypes of attention-deficit/hyperactivity disorder: results from a clinically referred sample. J Am Acad Child Adolesc Psychiatry 37 2 (1998) 185-193
15. Seeman P., and Madras B.K. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 3 5 (1998) 386-396
16. Bush G., Valera E.M., and Seidman L.J. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry 57 11 (2005) 1273-1284
17. Spencer T.J., Biederman J., Madras B.K., et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry 57 11 (2005) 1293-1300
18. di Michele F., Prichep L., John E.R., et al. The neurophysiology of attention-deficit/hyperactivity disorder. Int J Psychophysiol 58 1 (2005) 81-93
19. Bussing R., Zima B.T., Gary F.A., et al. Use of complementary and alternative medicine for symptoms of attention-deficit hyperactivity disorder. Psychiatr Serv 53 9 (2002) 1096-1102
20. Chan E. The role of complementary and alternative medicine in attention-deficit hyperactivity disorder. J Dev Behav Pediatr 23 1 Suppl (2002) S37-S45
21. Chan E., Rappaport L.A., and Kemper K.J. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr 24 1 (2003) 4-8
22. Cala S., Crismon M.L., and Baumgartner J. A survey of herbal use in children with attention-deficit-hyperactivity disorder or depression. Pharmacotherapy 23 2 (2003) 222-230
23. Feingold B. Why your child is hyperactive (1975), Random House, New York
24. Mattes J.A., and Gittelman R. Effects of artificial food colorings in children with hyperactive symptoms. A critical review and results of a controlled study. Arch Gen Psychiatry 38 6 (1981) 714-718
25. Wender E.H. The food additive-free diet in the treatment of behavior disorders: a review. J Dev Behav Pediatr 7 1 (1986) 35-42
26. McCann D., Barrett A., Cooper A., et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet 5 (2007) 5
27. Ricci G., Capelli M., Miniero R., et al. A comparison of different allergometric tests, skin prick test, Pharmacia UniCAP and ADVIA Centaur, for diagnosis of allergic diseases in children. Allergy 58 1 (2003) 38-45
28. Boris M., and Mandel F.S. Foods and additives are common causes of the attention deficit hyperactive disorder in children. Ann Allergy 72 5 (1994) 462-468
29. Egger J., Carter C.M., Graham P.J., et al. Controlled trial of oligoantigenic treatment in the hyperkinetic syndrome. Lancet 1 8428 (1985) 540-545
30. Wolraich M.L., Lindgren S.D., Stumbo P.J., et al. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. N Engl J Med 330 5 (1994) 301-307
31. Hoover D.W., and Milich R. Effects of sugar ingestion expectancies on mother-child interactions. J Abnorm Child Psychol 22 4 (1994) 501-515
32. Schnoll R., Burshteyn D., and Cea-Aravena J. Nutrition in the treatment of attention-deficit hyperactivity disorder: a neglected but important aspect. Appl Psychophysiol Biofeedback 28 1 (2003) 63-75
33. Scholastic Parent & Child. Turn off the TV to fight fat-and ADHD: television commercials can affect your child's diet, and in turn, his learning. Scholastic Inc (2007). [online article]. Available at: http://content.scholastic.com/browse/article.jsp?id=1441 Accessed September 5, 2007
34. Burgess J.R., Stevens L., Zhang W., et al. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr 71 1 Suppl (2000) 327S-330S
35. Richardson A.J. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 18 2 (2006) 155-172
36. Voigt R.G., Llorente A.M., Jensen C.L., et al. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 139 2 (2001) 189-196
37. Stevens L.J., Zentall S.S., Deck J.L., et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 62 4 (1995) 761-768
38. Sinn N., and Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 28 2 (2007) 82-91
39. Butnik S.M. Neurofeedback in adolescents and adults with attention deficit hyperactivity disorder. J Clin Psychol 61 5 (2005) 621-625
40. Monastra V.J., Monastra D.M., and George S. The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. Appl Psychophysiol Biofeedback 27 4 (2002) 231-249
41. Fuchs T., Birbaumer N., Lutzenberger W., et al. Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: a comparison with methylphenidate. Appl Psychophysiol Biofeedback 28 1 (2003) 1-12
42. Lyon M.R., Cline J.C., Totosy de Zepetnek J., et al. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study. J Psychiatry Neurosci 26 3 (2001) 221-228
43. Van Oudheusden L.J., and Scholte H.R. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 67 1 (2002) 33-38
44. Trebaticka J., Kopasova S., Hradecna Z., et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol. Eur Child Adolesc Psychiatry 15 6 (2006) 329-335
45. Jensen P.S., and Kenny D.T. The effects of yoga on the attention and behavior of boys with Attention-Deficit/hyperactivity Disorder (ADHD). J Atten Disord 7 4 (2004) 205-216
46. Khilnani S., Field T., Hernandez-Reif M., et al. Massage therapy improves mood and behavior of students with attention-deficit/hyperactivity disorder. Adolescence 38 152 (2003) 623-638
47. Bilici M., Yildirim F., Kandil S., et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 28 1 (2004) 181-190
48. Akhondzadeh S., Mohammadi M.R., and Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. [ISRCTN64132371]. BMC Psychiatry 4 1 (2004) 9
49. Konofal E., Lecendreux M., Arnulf I., et al. Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 158 12 (2004) 1113-1115
50. Sever Y., Ashkenazi A., Tyano S., et al. Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. Neuropsychobiology 35 4 (1997) 178-180
51. Haslam R.H., Dalby J.T., and Rademaker A.W. Effects of megavitamin therapy on children with attention deficit disorders. Pediatrics 74 1 (1984) 103-111
52. Altunc U., Pittler M.H., and Ernst E. Homeopathy for childhood and adolescence ailments: systematic review of randomized clinical trials. Mayo Clin Proc 82 1 (2007) 69-75
53. Strauss L. The efficacy of a homeopathic preparation in the management of attention deficit hyperactivity disorder. Journal of Biomedical Therapy 18 2 (2000) 197-201
54. Frei H., Everts R., von Ammon K., et al. Homeopathic treatment of children with attention deficit hyperactivity disorder: a randomised, double blind, placebo controlled crossover trial. Eur J Pediatr 164 12 (2005) 758-767
55. Jacobs J., Williams A.L., Girard C., et al. Homeopathy for attention-deficit/hyperactivity disorder: a pilot randomized-controlled trial. J Altern Complement Med 11 5 (2005) 799-806
56. Louv R. Last child in the woods: saving our children from nature-deficit disorder (2005), Algonquin Books of Chapel Hill, New York
57. Kuo F.E., and Taylor A.F. A potential natural treatment for attention-deficit/hyperactivity disorder: evidence from a national study. Am J Public Health 94 9 (2004) 1580-1586
58. Braun J.M., Kahn R.S., Froehlich T., et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect 114 12 (2006) 1904-1909
59. Szpir M. New thinking on neurodevelopment. Environ Health Perspect 114 2 (2006) A100-A107
60. Center for Disease Control and Prevention. Prevalence of the autism spectrum disorders in multiple areas of the United States surveillance years 2000 and 2002. National Center on Birth Defects and Developmental Disabilities. 2007; [website] Available at: http://www.cdc.gov/ncbddd/dd/addmprevalence.htm. Accessed September 17,2007.
61. Bertrand J., Mars A., Boyle C., et al. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics 108 5 (2001) 1155-1161
62. Gurney J.G., Fritz M.S., Ness K.K., et al. Analysis of prevalence trends of autism spectrum disorder in Minnesota. Arch Pediatr Adolesc Med 157 7 (2003) 622-627
63. Muhle R., Trentacoste S.V., and Rapin I. The genetics of autism. Pediatrics 113 5 (2004) E472-E486
64. Shastry B.S. Molecular genetics of autism spectrum disorders. J Hum Genet 48 10 (2003) 495-501
65. Hanson E., Kalish L.A., Bunce E., et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord 37 4 (2007) 628-636
66. Harrington J.W., Rosen L., Garnecho A., et al. Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. J Dev Behav Pediatr 27 2 Suppl (2006) S156-S161
67. Levy S.E., Mandell D.S., Merhar S., et al. Use of complementary and alternative medicine among children recently diagnosed with autistic spectrum disorder. J Dev Behav Pediatr 24 6 (2003) 418-423
68. Wong H.H., and Smith R.G. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord 36 7 (2006) 901-909
69. Horvath K., Papadimitriou J.C., Rabsztyn A., et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 135 5 (1999) 559-563
70. Torrente F., Ashwood P., Day R., et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry 7 4 (2002) 375-382 334
71. Rosseneu S. Aerobic gut flora in children with autism specturm disorder and gastrointestinal symptoms. Presented at: Defeat Autism Now Conference. San Diego (CA), October 3, 2003.
72. Sandler R.H., Finegold S.M., Bolte E.R., et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 15 7 (2000) 429-435
73. D'Eufemia P., Celli M., Finocchiaro R., et al. Abnormal intestinal permeability in children with autism. Acta Paediatr 85 9 (1996) 1076-1079
74. Horvath K., and Perman J.A. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep 4 3 (2002) 251-258
75. Lucarelli S., Frediani T., Zingoni A.M., et al. Food allergy and infantile autism. Panminerva Med 37 3 (1995) 137-141
76. Jyonouchi H., Sun S., and Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology 46 2 (2002) 76-84
77. Connolly A.M., Chez M.G., Pestronk A., et al. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr 134 5 (1999) 607-613
78. Singh V.K., Warren R., Averett R., et al. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr Neurol 17 1 (1997) 88-90
79. Cabanlit M., Wills S., Goines P., et al. Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann N Y Acad Sci 1107 (2007) 92-103
80. James S.J., Cutler P., Melnyk S., et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80 6 (2004) 1611-1617
81. Yorbik O., Sayal A., Akay C., et al. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids 67 5 (2002) 341-343
82. McGinnis W.R. Oxidative stress in autism. Altern Ther Health Med 10 6 (2004) 22-36 quiz 37, 92
83. Palmer R.F., Blanchard S., Stein Z., et al. Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas. Health Place 12 2 (2006) 203-209
84. Ip P., Wong V., Ho M., et al. Mercury exposure in children with autistic spectrum disorder: case-control study. J Child Neurol 19 6 (2004) 431-434
85. Adams J.B., Romdalvik J., Ramanujam V.M., et al. Mercury, lead, and zinc in baby teeth of children with autism versus controls. J Toxicol Environ Health A 70 12 (2007) 1046-1051
86. Bradstreet J., Geier D., DKartzinel J., et al. A case-control study of mercury burden in children with autistic spectrum disorders. Journal of American Physicians and Surgeons 8 3 (2003) 76-79
87. Vancassel S., Durand G., Barthelemy C., et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 65 1 (2001) 1-7
88. Bryson S.E., Rogers S.J., and Fombonne E. Autism spectrum disorders: early detection, intervention, education, and psychopharmacological management. Can J Psychiatry 48 8 (2003) 506-516
89. Sinha Y., Silove N., Wheeler D., et al. Auditory integration training and other sound therapies for autism spectrum disorders: a systematic review. Arch Dis Child 91 12 (2006) 1018-1022
90. Knivsberg A.M., Reichelt K.L., Hoien T., et al. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci 5 4 (2002) 251-261
91. Patrick L., and Salik R. The effect of essential fatty acid supplementation on language development and learning skills in autism and asperger's syndrome. Autism-Asperger's Digest (2005) 36-37
92. Amminger G.P., Berger G.E., Schafer M.R., et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 61 4 (2007) 551-553
93. Richardson A.J., and Montgomery P. The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 115 5 (2005) 1360-1366
94. Walsh W. Metallothionein and autism. Presented at: Defeat Autism Now Conference. San Diego (CA), October 3, 2003.
95. James S.J., Melnyk S., Jernigan S., et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 141 8 (2006) 947-956